Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847698 | 0.84 | CA1 (0.44) | TRPV4NT5EKDM4EALDH1A1HDAC4 | |
| SCHEMBL17113669 | 0.82 | TRPV4 (0.39) | TRPV4KDM4EALDH1A1ADRA2AADRA2B | |
| SCHEMBL29744288 | 0.82 | TRPV4 (0.39) | TRPV4KDM4EALDH1A1ADRA2AADRA2B | |
| SCHEMBL18397012 | 0.82 | TRPV4 (0.39) | TRPV4NT5EKDM4EALDH1A1ADRA2A | |
| SCHEMBL180474 | 0.81 | ABL1 (0.48) | TRPV4KDM4EALDH1A1ATML3MBTL1 | |
| SCHEMBL21327422 | 0.79 | GRM5 (0.40) | TRPV4KDM4EDAO | |
| SCHEMBL18151841 | 0.79 | MLYCD (0.43) | TRPV4KDM4EALDH1A1ADRA2AADRA2B | |
| SCHEMBL2599920 | 0.78 | NPC1 (0.52) | KDM4EALDH1A1HDAC4ADRA2AATM | |
| SCHEMBL20298748 | 0.77 | GBA1 (0.43) | TRPV4KDM4EALDH1A1ADRA2AADRA2B | |
| SCHEMBL3817535 | 0.77 | ALDH1A1 (0.38) | TRPV4KDM4EALDH1A1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022130403-A1 | NEW QUATERNARY AMMONIUM SALTS FOR TRIFLUOROMETHYLATION AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-06-23 | — | — | WO | claimed |
| CN-105622491-A | Process for synthesizing 6-(trifluoromethyl)pyridine-3-carboxaldehyde | ZHAO JIANYING | 2016-06-01 | — | — | CN | claimed |
| CN-105566208-A | Synthetic process of 6-(trifluoromethyl)pyridine-3-carboxaldehyde | QINGDAO SHOUTAI AGRICULTURAL SCIENCE & TECH CO LTD | 2016-05-11 | — | — | CN | claimed |
| EP-3433239-B1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12637454-B2 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| EP-3599854-B1 | PYRROLIDINONES AND A PROCESS TO PREPARE THEM | FMC CORP (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260022095-A1 | COMPOUNDS USEFUL FOR THE PREPARATION OF VARIOUS AGROCHEMICALS AND MARKERS THEREOF | ADAMA AGAN LTD. (IL) | 2026-01-22 | — | — | US | disclosed |
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2026-01-20 | — | — | US | disclosed |
| US-12516046-B2 | 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | disclosed |
| WO-2005023260-A1 | 1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005014571-A1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004101546-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004074290-A1 | SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2004-09-02 | — | — | WO | disclosed |
| US-20040157890-A1 | Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors | GLAXO GROUP LIMITED (GB) | 2004-08-12 | — | — | US | disclosed |
| EP-1392674-A1 | FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GLAXO GROUP LIMITED (GB) | 2004-03-03 | — | — | EP | disclosed |
| US-6653258-B1 | Pyridinyl-substituted- methyl 3-methoxy-2-phenylacrylate derivatives; agricultural miticides and nematocides | SYNGENTA LIMITED (GB) | 2003-11-25 | — | — | US | disclosed |
| WO-2002092590-A1 | FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GLAXO GROUP LIMITED (GB) | 2002-11-21 | — | — | WO | disclosed |
| US-5438059-A | Derivatives of propenoic acid; stereoisomers; applying to plants | ZENECA LIMITED (GB) | 1995-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, GAA | TRPV4 1824/4885NT5E 1016/4885KDM4E 877/4885 |
| US-20040157890-A1 | Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors | PPARG, PPARD, PPARA | TRPV4 291/4885NT5E 3385/4885KDM4E 4485/4885 |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | TRPV4 2184/4885NT5E 1978/4885KDM4E 4580/4885 |
| US-12637454-B2 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | MGLL, LIPA, LIPC | TRPV4 4794/4885NT5E 3382/4885KDM4E 1950/4885 |
| US-20260022095-A1 | COMPOUNDS USEFUL FOR THE PREPARATION OF VARIOUS AGROCHEMICALS AND MARKERS THEREOF | TET1, FOXK1, TET3 | TRPV4 571/4885NT5E 2030/4885KDM4E 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.